Poor
Poorly Aligned
Patient Risk:
Low
Summary
The AI-generated claims do not reflect the FDA-approved prescribing information; no substantive on-label indications, dosing, safety, or mechanism statements are present in the claims, and many assertions are not supported by the label.
Category Scores
Accurate Statements
Unsupported Statements
Tigecycline is a glycylcycline antibiotic.
Label describes tigecycline as a tetracycline class antibacterial (12.1); glycylcycline is not stated in the label text provided.
Tigecycline is a broad-spectrum antibiotic.
Label does not explicitly use the term 'broad-spectrum'; no explicit statement in the provided label text to categorize as such.
Tigecycline was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).
Label confirms indications for cSSSI and CABP but does not specify an approval year (2005).
Tigecycline works by inhibiting protein synthesis in bacteria.
Label indicates tigecycline is a tetracycline-class antibacterial (12.1) but does not provide an explicit mechanism statement in the text provided.
Tigecycline binds to the 30S subunit of the bacterial ribosome.
Label text provided does not explicitly state this binding site.
Tigecycline prevents the attachment of aminoacyl-tRNA to the ribosome.
Label text provided does not explicitly describe this mechanism.
Tigecycline thereby inhibits protein synthesis.
Label text provided does not explicitly state this mechanism beyond the class designation.
Tigecycline has a broader spectrum of activity and is more resistant to resistance mechanisms than tetracyclines.
Label text provided does not include comparative spectrum/resistance statements relative to tetracyclines.
The minimum inhibitory concentration (MIC) of tigecycline against 90% of Bacteroides fragilis isolates is 0.25-1 μg/mL.
MIC data for B. fragilis are not provided in the accessible label text.
Tigecycline was effective against B. fragilis in 92% of cases.
No such efficacy percentage for B. fragilis is present in the provided label text.
Tigecycline had a higher efficacy rate against B. fragilis than metronidazole (92% vs. 76%).
Label does not provide comparative efficacy percentages for B. fragilis against metronidazole.
Tigecycline had a higher efficacy rate against B. fragilis than imipenem (92% vs. 84%).
Label does not provide such B. fragilis efficacy comparisons with imipenem.
Tigecycline had a higher efficacy rate against B. fragilis than meropenem (92% vs. 80%).
Label does not provide such B. fragilis efficacy comparisons with meropenem.
Resistance to tigecycline is a growing concern, particularly in the context of B. fragilis.
Label text provided does not discuss resistance trends for B. fragilis.
12% of B. fragilis isolates were resistant to tigecycline.
No resistance prevalence data for tigecycline in B. fragilis is present in the provided label.
Resistance to tigecycline was not a significant issue in the treatment of B. fragilis infections.
No such statement about resistance impact is in the label text provided.
Resistance to tigecycline may limit its use as a treatment option for B. fragilis infections.
Label does not discuss resistance-limiting use in B. fragilis context.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
No on-label indications or dosing information reflected in the claims; no explicit reference to cSSSI and CABP indications from label text beyond generic mention.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Claims contain no explicit safety signals; emphasis on non-supported statements rather than patient risk.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
No claims align with on-label indications, dosing, or mechanism details; multiple statements are not supported by the label.
Suggested Improvement
Restrict claims to on-label indications (cSSSI, CABP, intra-abdominal infections as specified), mechanism as described by the label (tetracycline-class antibacterial with details in 12.4), and avoid efficacy or resistance data not present in the labeling.